COLARIS AP ^®: Genetic Testing for Adenomatous Polyposis Colon Cancer Syndromes

COLARIS AP ^® detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP) and MYH -associated polyposis (MAP). The most common adenomatous polyposis conditions are thought to account for approximately two percent of all colon cancer.

COLARIS AP ^® uses a simple blood or oral rinse sample to determine if patients have an APC or MYH mutation. Knowing the results may help patients and their healthcare providers act before cancer has a chance to develop.

Myriad has developed a Hereditary Cancer Quiz that patients and their healthcare providers can use to help identify potential candidates for genetic testing with COLARIS AP ^®.

Benefits of COLARIS AP ^® Testing

The results of the COLARIS AP ^® test enable patients and their healthcare professionals to develop an individualized medical management plan to significantly reduce the risk of cancer. COLARIS AP ^® helps healthcare professionals to:

• Personalize patient care and increase clinical efficiency by targeting increased surveillance and other interventions specifically to individuals with APC or MYH gene mutation(s);
• Improve patient compliance with tailored screening recommendations and preventive measures;
• Significantly improve outcomes and reduce medical costs through early diagnosis and treatment of cancer;
• Counsel patients and their family members on the underlying cause of the cancer or adenomas;
• Avoid unnecessary interventions involving family members who do not test positive for the mutation(s) known to be in the family; and
• Differentiate between AFAP, MAP and Lynch syndrome.

Medical Management and COLARIS AP ^®

If a COLARIS AP ^® test result confirms the presence of adenomatous polyposis syndromes, the following medical management options may help reduce or even eliminate the risk of cancer.

Attenuated FAP (AFAP):

• Increased surveillance
• Surgical management

MYH -Associated Polyposis (MAP):

• For patients who have MAP, medical society management recommendations include colonoscopies every one to two years starting at age 25-30, upper endoscopies every three to five years starting at age 30-35, and surgical options. The most appropriate medical management will vary based upon the patient’s clinical presentation.
• For MYH mutation carriers (one mutation), medical management should be determined by clinical findings and a personal and family history of colorectal polyps and/or cancer. Current data are limited but suggest that any increase in risk, if present, is likely to be small.

Familial Adenomatous Polyposis (FAP):

• Increased surveillance
• Chemoprevention
• Surgical management

For more healthcare professional information  please visit MyriadPro.com.